AI in Life Sciences — Production Use Cases in 2025

Life sciences — pharmaceuticals, biotech, medical devices, clinical research — is a domain where AI has been pitched as transformative for years. The realistic deployments are narrower than the marketing positions. Through 2024 and into 2025, the production use cases that have moved past pilot share recognisable shape.

This piece is a practitioner view of where AI in life sciences is actually shipping in 2025 — what's working, what isn't, and what the discipline that distinguishes shipped systems from stalled pilots looks like.

What life sciences workflows actually involve

A life sciences enterprise handles:

• R&D documentation and literature — vast volumes of scientific publications, internal research records, regulatory filings
• Clinical trials — protocol design, site management, monitoring, data management, regulatory submissions
• Regulatory affairs — submissions to FDA, EMA, PMDA, NMPA, and other authorities; lifecycle maintenance
• Pharmacovigilance — safety reporting, signal detection, periodic safety updates
• Manufacturing and quality — batch records, deviations, CAPA, validation
• Medical communications — promotional and non-promotional materials, scientific exchange
• Commercial operations — sales enablement, healthcare provider engagement
• Patient-facing services — patient support programmes, education, registry management

Each is a target for AI. The patterns differ.

Where AI is shipping in 2025

Regulatory submission drafting

The largest single category we are seeing. AI drafts regulatory documents from source materials — clinical study reports, IND/NDA narratives, modules of the Common Technical Document. The team curates and verifies.

The impact: drafting time drops; the team's effort moves to review and quality assurance, which is where the judgment value lies.

The constraint: the outputs require thorough human verification before submission. AI does not produce regulator-ready content directly.

Literature analysis and review

Systematic literature reviews, periodic safety updates, competitive intelligence. AI processes the literature at scale; researchers focus on synthesis and judgment.

The work is well-suited to the AI capability — high-volume, document-heavy, structured outputs.

Adverse event coding and review

AE intake from various sources gets processed by AI — coded against MedDRA, classified by seriousness, flagged for follow-up. Safety scientists review the AI's outputs.

This is one of the workflows where AI has clear quality and throughput benefits. The pattern works because the coding is bounded; the validation is structured; the audit posture is well-understood.

Clinical trial protocol drafting

AI drafts trial protocols based on therapeutic area, indication, and study type. Researchers refine, customise, and approve.

The pattern accelerates protocol development; it doesn't replace the expertise of trial designers.

Medical writing assistance

Scientific publications, abstract drafting, poster content. AI produces drafts that medical writers refine. The writing throughput goes up; the writers' role shifts toward editing and judgment.

Pharmacovigilance signal detection augmentation

Signals in adverse event data are detected by statistical methods plus AI augmentation. The AI surfaces patterns the statistical methods might miss; scientists investigate.

Clinical operations workflow

Site monitoring, query management, deviation handling. AI handles routine, escalates the unusual.

Manufacturing batch record analysis

AI reviews batch records, surfaces deviations, drafts initial CAPA. Quality reviewers verify and decide.

Where AI is not yet shipping reliably

Diagnostic decision-making

For clinical diagnostic decisions, AI assists in specific imaging applications but does not generally substitute for clinician judgment. The regulatory posture, the liability profile, and the reliability requirements remain demanding.

Therapeutic development end-to-end

The vision of AI-discovered, AI-developed therapeutics remains aspirational. AI accelerates specific steps (target identification, molecular design, trial enrichment) without changing the overall discovery process timeline meaningfully.

Autonomous safety decisions

Pharmacovigilance decisions about labelling changes, safety actions, regulatory communication remain firmly human. AI assists with the volume; humans make the decisions.

Promotional content compliance

The compliance review of promotional materials is high-stakes. AI assists with first-pass screening; final approval remains a regulated human decision.

Patient-facing direct interaction

Direct AI interaction with patients (chatbots making clinical statements) is constrained by regulatory frameworks. Patient support programmes use AI carefully behind human reviewers.

What makes life sciences AI deployments succeed

The patterns common to successful deployments:

Strict audit trails

Every AI invocation, every output, every human review is logged with sufficient detail to defend the decision. The audit posture matches the rest of the institution.

Validation against regulatory expectations

The AI's behaviour is validated against the same standards as other consequential systems. Documentation, evidence, periodic review.

Human-in-the-loop at the right places

AI assists with the volume work; humans decide on the consequential work. The boundary is explicit.

Curated knowledge bases

AI's quality depends on the knowledge it has access to. Life sciences enterprises invest in curated knowledge bases (literature corpora, internal research, regulatory precedent) as platform investments.

Cross-functional governance

Engineering, medical, regulatory, legal, IT — all engage in governance of life sciences AI initiatives. None alone is sufficient.

Realistic expectations

The successful deployments don't claim transformation; they claim productivity. The productivity is real; the transformation framing produces over-promised outcomes.

What we keep seeing

Patterns in life sciences AI engagements in 2025:

Regulatory submission drafting is the dominant use case. The fit is good; the productivity gain is meaningful; the risk profile is manageable with appropriate review.

Pharmacovigilance is the second wave. As regulatory comfort with AI in pharmacovigilance grows, more workloads ship.

Clinical operations gets attention but slower deployment. The regulated nature of trials slows AI adoption; the value when it lands is significant.

Manufacturing and quality are conservative. GMP environments require careful change management; AI deployments proceed cautiously.

The audit infrastructure dominates the engineering work. The compliance posture requires detailed, retainable, examinable logs.

Vendors are abundant; few are mature. Many AI vendors targeting life sciences; few have the regulatory understanding and validation pedigree.

What we recommend

For life sciences enterprises building AI capability in 2025:

1. Start with regulatory submission drafting if applicable. High-yield, well-bounded, regulatory acceptance is rising.
2. Invest in the audit infrastructure as a first-class concern.
3. Curate the knowledge bases. The AI's quality is bounded here.
4. Maintain human-in-the-loop at consequential decision points. The autonomy aspirations are not aligned with regulatory comfort.
5. Engage regulatory affairs early in AI initiatives. The regulator's expectations shape the work.
6. Choose vendors with regulatory understanding and validation experience.
7. Measure on outcomes — submission time, signal detection rate, throughput per scientist. Avoid the transformation framing.

AI in life sciences in 2025 is a domain where the value is real, the productivity gains are measurable, and the discipline that produces successful deployments is recognisable. The enterprises that respect the regulatory and quality posture ship sustainable capability. The enterprises that pursue autonomy or transformation produce expensive failures and regulatory friction. The work is engineering and clinical, applied with the rigour the domain has always required.